Bernard Brigonnet
Direktor/Vorstandsmitglied bei Proterris (Portugal) - Investigação e Desenvolvimento
Profil
Bernard Brigonnet is a professional with experience in various firms.
He is currently working as a Director at Proterris (Portugal) -.
Investigação e Desenvolvimento.
Previously, he worked as a Principal at Bristol Myers Squibb Co., Merck & Co., Inc., GSK Plc, EMD Serono, Inc., IDM Pharma, Inc., and Baylor Research Institute.
He also served as the Chief Business Officer at Biotecnol-Serviços e Desenvolvimento SA. Brigonnet completed his undergraduate degree from ESCP Europe Campus Paris.
Aktive Positionen von Bernard Brigonnet
| Unternehmen | Position | Beginn |
|---|---|---|
Proterris (Portugal) - Investigação e Desenvolvimento
 Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal. | Direktor/Vorstandsmitglied | 09.09.2009 |
Ehemalige bekannte Positionen von Bernard Brigonnet
| Unternehmen | Position | Ende |
|---|---|---|
| Baylor Research Institute | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
Biotecnol-Serviços e Desenvolvimento SA
 Biotecnol-Serviços e Desenvolvimento SA Miscellaneous Commercial ServicesCommercial Services Biotecnol-Serviços e Desenvolvimento SA engages in the discovery, engineering, and development of multifunctional antibody molecules, directed to key therapeutic targets. The firm operates as a biopharmaceutical company working in the field of immuno-oncology. It uses Tribody technology to develop a pipeline of in-house discovered products in selected oncology indications. The company was founded in 1997 and is headquartered in Oeiras, Portugal. | Direktor/Vorstandsmitglied | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Bernard Brigonnet
| ESCP Europe Campus Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Proterris (Portugal) - Investigação e Desenvolvimento
Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal. | Health Technology |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
Biotecnol-Serviços e Desenvolvimento SA
Biotecnol-Serviços e Desenvolvimento SA Miscellaneous Commercial ServicesCommercial Services Biotecnol-Serviços e Desenvolvimento SA engages in the discovery, engineering, and development of multifunctional antibody molecules, directed to key therapeutic targets. The firm operates as a biopharmaceutical company working in the field of immuno-oncology. It uses Tribody technology to develop a pipeline of in-house discovered products in selected oncology indications. The company was founded in 1997 and is headquartered in Oeiras, Portugal. | Commercial Services |
| Baylor Research Institute |
